Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Patent
1996-08-28
1998-07-14
Kight, John
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
424 165, 424 111, 534 14, 530300, 530328, 530329, 530330, A61K 5100, A61M 3614
Patent
active
057800065
ABSTRACT:
For use in imaging sites of diagnostic interest within the body, the present invention provides radionuclide chelators, optionally coupled to targeting molecules such as peptides of the formula: ##STR1##
REFERENCES:
patent: 5480970 (1996-01-01), Pollak et al.
patent: 5569745 (1996-10-01), Goodbody et al.
patent: 5662885 (1997-09-01), Pollak et al.
Pollack et al (1994), Journal of Nuclear Medicine, vol. 35, No. 5, pp. Abstract No. 171, "Imaging Inflammation with Novel Peptdic Technetium-99m Chelators Linked to a Chemotectic Peptide".
Goodbody Anne
Pollak Alfred
Jones Dameron
Kight John
Resolution Pharmaceuticals Inc.
LandOfFree
Peptide derived radionuclide chelators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide derived radionuclide chelators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide derived radionuclide chelators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1879119